title: Nivolumab: The New Second Line Treatment for Advanced Renal-cell Carcinoma Commentary on: Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma.
authors.affiliation: Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Edmund C P
authors.initials: EC
authors.lastname: Chedgy
authors.affiliation: Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Peter C
authors.initials: PC
authors.lastname: Black
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D020123:Sirolimus / Q000031:analogs & derivatives*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D020123:Sirolimus